Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906395 · ClinicalTrials.gov registry record · Phase 3
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by Tolmar.
- Active
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT04906395 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by Tolmar. The registered enrollment target is 250 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04906395, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by Tolmar.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative breast cancer. The Screening Period will be conducted in two parts: 1) an abbreviated, initial screening where premenopausal status will be determined prior to neoadjuvant or adjuvant chemotherapy (if planned) and 2) the full screening assessment conducted after neoadjuvant or adjuvant chemotherapy (or for subjects who enter the study without having received chemotherapy). Following the Screening Period, eligible subjects will enter into the 48 week Treatment Period in 1 of 2 groups: those who will receive tamoxifen concurrently with TOL2506 or those who will initiate therapy with an AI (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of TOL2506, upon confirmation that estradiol (E2) levels of \< 20 pg/mL (testosterone levels \< 50 ng/dL in males) have been achieved. After Week 12, subjects will be allowed to switch from receiving an AI to receiving tamoxifen or from tamoxifen to AI at the discretion of the Investigator. However, a switch is not permitted 28 days prior to a dosing visit (eg, Week 24, 36, and 48 where a pre-dose blood sample for PK and PD analysis will be drawn). At the end of the Treatment Period, upon completion of the End of Study Visit (Visit 9, Week 48) subjects may be eligible to participate in a Safety Extension Study under a separate Protocol.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG TOL2506
- DRUG Letrozole Tablets
- DRUG Anastrozole Tablets
- DRUG Exemestane Tablets
Study Locations (20)
Texas
- Texas Oncology-Austin - Austin
- Texas Oncology- Dallas Presbyterian Hospital - Dallas
- Texas Oncology- San Antonio - New Braunfels
- Texas Oncology- Northeast Texas - Tyler
- Texas Oncology- Deke Slayton Cancer Center - Webster
Tennessee
- Tennessee Oncology, PLLC - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Córdoba Province
- Instituto Oncologico de Cordoba (IONC) - Córdoba
- Centro Privado de RMI Rio Cuarto - Río Cuarto
California
- Marin Cancer Care, Inc - Greenbrae
Colorado
- Cypress Hematology and Oncology - Parker
Illinois
- Mount Sinai Hospital - Chicago
Kentucky
- Baptist Health Louisville - Louisville
Maryland
- Maryland Oncology Hematology, P.A. - Glenn Dale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906395
The ClinicalTrials.gov registry entry for NCT04906395 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Tolmar, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Tamoxifen is the first listed.
NCT04906395 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Tennessee, Córdoba Province.
Frequently Asked Questions
What is clinical trial NCT04906395 about?
NCT04906395 is a clinical study titled "Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer". This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative breast cancer. The Screening Perio...
What is the current status of trial NCT04906395?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2021-07-01. Estimated completion is 2026-04-30.
What conditions does trial NCT04906395 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04906395?
The interventions under investigation include: Tamoxifen (DRUG), TOL2506 (DRUG), Letrozole Tablets (DRUG), Anastrozole Tablets (DRUG), Exemestane Tablets (DRUG).
Who is sponsoring clinical trial NCT04906395?
This trial is sponsored by Tolmar, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906395 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.